title: Life-threatening hypocalcemia associated with denosumab in a patient with moderate renal insufficiency.
abstract: Denosumab, a human monoclonal antibody to the receptor activator of nuclear factor-κB ligand, is a novel therapy to osteoporotic fracture and skeletal-related events in patients with bone metastases. Hypocalcemia is its known adverse effect, although it is generally mild and transient and usually occurs in patients with severe chronic kidney disease or end-stage renal disease. We reported a case 61-year-old woman who received a single dose of denosumab and developed severe symptomatic hypocalcemia associated with prolong QTc interval requiring hospitalization for intravenous calcium.
authors: Department of Internal Medicine, Bassett Medical Center and Columbia University College of Physicians and Surgeons, Cooperstown, NY 13326, USA. Patompong.Ungprasert@bassett.org
authors: Patompong
authors: P
authors: Ungprasert
authors: Wisit
authors: W
authors: Cheungpasitporn
authors: Narat
authors: N
authors: Srivali
authors: Wonngarm
authors: W
authors: Kittanamongkolchai
authors: Edward F
authors: EF
authors: Bischof
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D001859:Bone Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000556:secondary; D001943:Breast Neoplasms / Q000473:pathology*; D000069448:Denosumab; D005260:Female; D006801:Humans; D006996:Hypocalcemia / Q000139:chemically induced* / Q000628:therapy; D008875:Middle Aged; D051437:Renal Insufficiency / Q000150:complications
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069448:Denosumab